These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 34141084

  • 1. SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression.
    Zhou H, Bai L, Xu R, McEachern D, Chinnaswamy K, Li R, Wen B, Wang M, Yang CY, Meagher JL, Sun D, Stuckey JA, Wang S.
    ACS Med Chem Lett; 2021 Jun 10; 12(6):996-1004. PubMed ID: 34141084
    [Abstract] [Full Text] [Related]

  • 2. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
    Zhou H, Bai L, Xu R, Zhao Y, Chen J, McEachern D, Chinnaswamy K, Wen B, Dai L, Kumar P, Yang CY, Liu Z, Wang M, Liu L, Meagher JL, Yi H, Sun D, Stuckey JA, Wang S.
    J Med Chem; 2019 Dec 26; 62(24):11280-11300. PubMed ID: 31747516
    [Abstract] [Full Text] [Related]

  • 3. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.
    Bai L, Zhou H, Xu R, Zhao Y, Chinnaswamy K, McEachern D, Chen J, Yang CY, Liu Z, Wang M, Liu L, Jiang H, Wen B, Kumar P, Meagher JL, Sun D, Stuckey JA, Wang S.
    Cancer Cell; 2019 Nov 11; 36(5):498-511.e17. PubMed ID: 31715132
    [Abstract] [Full Text] [Related]

  • 4. A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo.
    Kaneshige A, Bai L, Wang M, McEachern D, Meagher JL, Xu R, Wang Y, Jiang W, Metwally H, Kirchhoff PD, Zhao L, Jiang H, Wang M, Wen B, Sun D, Stuckey JA, Wang S.
    Nat Chem Biol; 2023 Jun 11; 19(6):703-711. PubMed ID: 36732620
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer.
    Li H, Wang L, Cao F, Yu D, Yang J, Yu X, Dong J, Qin JJ, Guan X.
    Front Pharmacol; 2022 Jun 11; 13():944455. PubMed ID: 36034876
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
    Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM.
    Cancer Res; 2003 Mar 15; 63(6):1270-9. PubMed ID: 12649187
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. SD-36 promotes growth inhibition and induces apoptosis via suppression of Mcl-1 in glioma.
    Kong S, Ge X, Li X, Liu Z, Zhang R, Yang M, Wang Z, Li Z.
    J Cell Mol Med; 2021 Sep 15; 25(17):8261-8270. PubMed ID: 34291563
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Lycorine Displays Potent Antitumor Efficacy in Colon Carcinoma by Targeting STAT3.
    Wu S, Qiu Y, Shao Y, Yin S, Wang R, Pang X, Ma J, Zhang C, Wu B, Koo S, Han L, Zhang Y, Gao X, Wang T, Yu H.
    Front Pharmacol; 2018 Sep 15; 9():881. PubMed ID: 30135654
    [Abstract] [Full Text] [Related]

  • 14. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
    Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J, Seiden MV.
    Mol Pharmacol; 2007 Nov 15; 72(5):1137-45. PubMed ID: 17675586
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity.
    Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, Jove R.
    Mol Cancer Ther; 2004 Dec 15; 3(12):1533-42. PubMed ID: 15634646
    [Abstract] [Full Text] [Related]

  • 16. LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo.
    Liu Z, Wang H, Guan L, Lai C, Yu W, Lai M.
    Br J Pharmacol; 2020 Jan 15; 177(2):298-313. PubMed ID: 31499589
    [Abstract] [Full Text] [Related]

  • 17. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo.
    Huang W, Dong Z, Chen Y, Wang F, Wang CJ, Peng H, He Y, Hangoc G, Pollok K, Sandusky G, Fu XY, Broxmeyer HE, Zhang ZY, Liu JY, Zhang JT.
    Oncogene; 2016 Feb 11; 35(6):783-92. PubMed ID: 26073084
    [Abstract] [Full Text] [Related]

  • 18. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
    Ma H, Yan D, Wang Y, Shi W, Liu T, Zhao C, Huo S, Duan J, Tao J, Zhai M, Luo P, Guo J, Tian L, Mageta L, Jou D, Zhang C, Li C, Lin J, Lv J, Li S, Lin L.
    Cancer Sci; 2019 Mar 11; 110(3):950-961. PubMed ID: 30648776
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice.
    Yang Z, Cai JH, Xie SJ, Li GX, Song WQ, Yan QH, Yan L, Zhang F.
    Chin Med J (Engl); 2011 Jun 11; 124(12):1854-61. PubMed ID: 21740845
    [Abstract] [Full Text] [Related]

  • 20. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3).
    Huang Q, Zhong Y, Li B, Ouyang S, Deng L, Mo J, Shi S, Lv N, Wu R, Liu P, Hu W, Zhang X, Wang Y.
    Eur J Med Chem; 2021 Oct 05; 221():113525. PubMed ID: 34000483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.